Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2008 by Office of Rare Diseases (ORD).
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Rare Diseases Clinical Research Network
Information provided by:
Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier:
NCT00319878
First received: April 28, 2006
Last updated: October 6, 2008
Last verified: October 2008
  Purpose

Aplastic anemia is a rare autoimmune disorder in which the bone marrow production of blood cells is greatly decreased or absent. Symptoms include fatigue, weakness, tiny reddish-purple marks on the skin, abnormal bruising, and bleeding from the gums, nose, or intestine. While some cases of aplastic anemia are caused by medications, toxic exposures, or inherited genes, most often the cause remains unknown. The purpose of this study is to determine the safety and efficacy of combining two drugs, sirolimus and cyclosporine, for treating individuals with aplastic anemia that has not responded to other treatments.


Condition Intervention Phase
Anemia, Aplastic
Drug: Sirolimus
Drug: Cyclosporine
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Trial of Sirolimus (Rapamune) and Cyclosporine in Patients With Refractory Aplastic Anemia

Resource links provided by NLM:


Further study details as provided by Office of Rare Diseases (ORD):

Primary Outcome Measures:
  • Safety and tolerability of sirolimus and cyclosporine in each stratum of participants [ Time Frame: Measured at Month 6 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Response rate [ Time Frame: Measured at Months 3 and 6 ] [ Designated as safety issue: No ]
  • Duration of hematologic response [ Time Frame: Measured at Month 6 ] [ Designated as safety issue: No ]
  • Rate of clonal disease evolution [ Time Frame: Measured at Month 6 ] [ Designated as safety issue: No ]
  • Survival [ Time Frame: Measured at Month 6 ] [ Designated as safety issue: No ]

Estimated Enrollment: 52
Study Start Date: May 2006
Estimated Study Completion Date: December 2009
Estimated Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Participants will be treated with sirolimus and cyclosporine. In phase I, each dose cohort will initially enroll three patients. If no dose-limiting toxicity (DLT) is observed by Day 28 in any patient of a cohort, then 3 patients will be treated with the next highest sirolimus dose. If 1 out of 3 patients in any cohort experiences a DLT, then 3 more patients will be enrolled in that cohort. If no more patients have a DLT by Day 28, then sirolimus dose escalation will proceed. If one or more patients experience a DLT then that dose level will be considered to be the maximum tolerated sirolimus dose, and Phase II patients will be treated at the next lowest level. Cyclosporine will be given as a twice daily oral dose.
Drug: Sirolimus

Oral loading dose followed by a once daily dose:

  • Cohort 1: Loading Dose - 1.2 mg; Daily Dose - 0.4 mg
  • Cohort 2: % Dose Increase - 100%; Loading Dose - 2.4 mg; Daily Dose - 0.8 mg
  • Cohort 3: % Dose Increase - 67%; Loading Dose - 3.9 mg; Daily Dose - 1.3 mg
  • Cohort 4: % Dose Increase - 50%; Loading Dose - 6.0 mg; Daily Dose - 2.0 mg
Drug: Cyclosporine
Dose of 5 mg/kg divided as a twice daily oral dose

Detailed Description:

The most successful treatment for aplastic anemia is bone marrow transplantation. However, few patients are eligible for this procedure. For others, treatment usually consists of immunosuppressive agents, such as antithymocyte globulin (ATG) and cyclosporine. Unfortunately, even with immunosuppressive therapy, relapse is common. New combinations of medications may offer alternative and more effective treatment options. Sirolimus and cyclosporine are two drugs routinely used to suppress the immune system and prevent rejection in patients who have received organ transplants. While cyclosporine has been proven effective for treating aplastic anemia, sirolimus has not been tested for this disease. This study will evaluate the safety and efficacy of sirolimus in combination with cyclosporine for treating individuals with aplastic anemia that has not responded to other treatments.

This study will last at least 6 months. Participants will first be screened to verify diagnosis of aplastic anemia. The screening will include a physical examination, blood test, bone marrow biopsy from the pelvic bone, and review of medications and medical history. Individuals who are eligible will then start the first treatment period. Participants will receive two medications: cyclosporine will be taken twice a day and sirolimus will be taken once a day. Depending on side effects, the doses of either drug may be temporarily stopped or lowered. On Day 1, blood will be drawn and females will undergo a pregnancy test. Subsequent study visits will occur weekly for the first month, every 2 weeks for 2 months, and then once a month for the remainder of the study. Each visit will include a physical examination, vital sign assessment, and review of side effects and medications. Blood tests will be performed weekly for the first 3 weeks, and then every 2 weeks.

After 6 months of treatment, if a participant has shown improvements in disease status without major side effects, the treatment will continue. Over time the doses may be lowered. If a participant has not improved while on the study medication, treatment will stop at 6 months. Whenever treatment is discontinued, the participant will again undergo a physical examination, blood tests, and bone marrow biopsy.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of moderate or severe aplastic anemia with bone marrow cellularity of less than 25%
  • Falls within one of the following descriptions at the time of the original diagnosis:

    1. For severe aplastic anemia, fulfills any two of the following three criteria: absolute neutrophil count less than 500/uL; absolute reticulocyte count less than 60,000/uL; and platelet count less than 20,000/uL
    2. For moderate aplastic anemia, fulfills any two of the following three criteria: absolute neutrophil count less than 1200/ul; hemoglobin less than 8 g/dL with corrected reticulocyte count less than 1%; and platelet count less than 60,000/uL (Note: Participants who have progressed from moderate to severe aplastic anemia prior to study entry will be classified as having severe aplastic anemia)
  • Diagnosis of refractory aplastic anemia, as defined by a failure to achieve at least a partial response to ATG within 6 months of treatment. Individuals who had a prior response to ATG but who have relapsed and not responded to salvage ATG are eligible. Individuals with relapsed disease who are not candidates for salvage ATG because they experienced a serious or life-threatening complication prior to ATG are also eligible.
  • A Karnofsky performance status of at least 60%
  • Adequate organ function, as defined by creatine levels less than 1.5 times the upper limit normal (ULN), and liver function tests (AST, bilirubin) less than 2 times the ULN
  • Women of childbearing age must be willing to use effective contraception throughout the study

Exclusion Criteria:

  • Received ATG treatment less than 6 months prior to study entry
  • Candidate for related allogeneic stem cell transplantation
  • Active uncontrolled infection
  • History of myelodysplastic syndrome or bone marrow cytogenetic abnormalities
  • History of Fanconi's anemia or other congenital form of aplastic anemia
  • Treatment with an investigational agent within 1 month of study entry
  • HIV infection
  • Pregnant or breastfeeding
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00319878

Contacts
Contact: Lynn Tihopu 310-794-0738
Contact: Meenal Chalukya 310-825-8091

Locations
United States, California
UCLA Center for Health Sciences Recruiting
Los Angeles, California, United States, 90095
Contact: Ronald Paquette, MD    310-206-5755    paquette@ucla.edu   
Principal Investigator: Ronald Paquette, MD         
United States, Florida
Lee Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33606
Contact: Alan List, MD         
Principal Investigator: Alan List, MD         
Principal Investigator: Hussain Saba, MD         
United States, Ohio
Taussig Cancer Center, Cleveland Clinic Foundation Recruiting
Cleveland, Ohio, United States, 44195
Contact: Jaroslaw P. Maciejewski, MD         
Principal Investigator: Jaroslaw P. Maciejewski, MD         
Principal Investigator: Mikkael Sekeres, MD         
United States, Pennsylvania
Penn State University Cancer Center Recruiting
Hershey, Pennsylvania, United States, 17033
Contact: Thomas Loughran, MD         
Principal Investigator: Thomas Loughran, MD         
Sponsors and Collaborators
Rare Diseases Clinical Research Network
  More Information

Publications:
Responsible Party: Ronald Paquette, MD, UCLA Division of Hematology/Oncology
ClinicalTrials.gov Identifier: NCT00319878     History of Changes
Other Study ID Numbers: RDCRN 5403, U54 RR19397-01, BMF 5403
Study First Received: April 28, 2006
Last Updated: October 6, 2008
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Anemia
Anemia, Aplastic
Hematologic Diseases
Bone Marrow Diseases
Cyclosporins
Cyclosporine
Sirolimus
Everolimus
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Therapeutic Uses
Dermatologic Agents
Antirheumatic Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Anti-Bacterial Agents

ClinicalTrials.gov processed this record on April 15, 2014